ObjectiveTo evaluate the antitumor activity of Periplaneta americana extract（PAE） against human-derived lung adenocarcinoma organoids（LUAD-PDOs） and to elucidate its potential mechanism based on transcriptomics. MethodsFresh tumor and adjacent normal tissues from patients with LUAD were collected to construct LUAD-PDOs and normal lung organoid（Nor-PDOs） models using 3D organoid culture technology. The effective intervention concentration of PAE was determined using the cell counting kit-8（CCK-8） assay. Experimental groups included the model group（LUAD-PDOs）， normal group， model administration group（LUAD-PDOs+PAE）， and normal administration group（Nor-PDOs+PAE）. Hematoxylin-eosin（HE） staining was used to observe the pathological structures of PDOs， immunohistochemistry（IHC） was performed to detect the expressions of the proliferation marker Ki-67 and lung adenocarcinoma differentiation markers cytokeratin-7（CK-7） and Napsin A， TUNEL staining was applied to detect cell apoptosis. RNA sequencing（RNA-Seq） was conducted to identify differentially expressed genes（DEGs）， followed by Gene Ontology（GO）， Kyoto Encyclopedia of Genes and Genomes（KEGG）， and Gene Set Enrichment Analysis（GSEA）， alongside protein-protein interaction（PPI） network analysis to screen core mechanisms. Finally， key targets were validated by integrating external database analysis with immunofluorescence（IF）. ResultsNor-PDOs and LUAD-PDOs that highly recapitulated the pathological characteristics of the primary tissues were successfully established. The CCK-8 assay determined that the effective intervention concentration of PAE was 16 g·L^-1. Morphological observation showed that Nor-PDOs exhibited lumen-forming structures， whereas LUAD-PDOs displayed dense， solid structures. CCK-8 and TUNEL assays revealed that， compared with the model group， PAE intervention inhibited the proliferation of LUAD-PDOs and promoted apoptosis in LUAD cells， while showing no significant effect on the viability of Nor-PDOs. Transcriptomic analysis identified 719 DEGs that were significantly reversed after PAE intervention（347 up-regulated and 372 down-regulated）（P<0.05）. GO enrichment analysis indicated that DEGs in the model administration group were significantly enriched in biological processes related to cell cycle regulation compared to the model group. KEGG pathway analysis revealed that PAE affected pathways related to proliferation and metabolism， including pathways in cancer and the p53 signaling pathway. GSEA further confirmed that PAE significantly enhanced the activity of the p53 signaling pathway（P<0.05）. PPI network analysis indicated that breast cancer type 1 susceptibility protein（BRCA1） and checkpoint kinase 1（CHEK1） were the core down-regulated targets in the p53 pathway. IF verified the high expression of BRCA1 and CHEK1 in LUAD-PDOs and their significant downregulation after PAE intervention（P<0.05）. Furthermore， survival analysis based on The Cancer Genome Atlas（TCGA） database indicated that low expression of BRCA1 and CHEK1 was significantly associated with prolonged overall survival in patients with LUAD（P<0.05）. ConclusionPAE effectively inhibits proliferation of LUAD-PDOs and promotes their apoptosis， its anti-tumor mechanism is potentially associated with the activation of the p53 signaling pathway， with BRCA1 and CHEK1 genes likely serving as key downstream targets for the effects of PAE.

Based on LI Gao's Academic Thought， focusing on the process of qi transformation and taking the regulation and restoration of metabolism and immunity as the entry point， a "source-pivot-convergence" diagnostic and therapeutic model for malignant tumors is constructed. In this model， spleen and stomach internal injury is the source of malignant tumor occurrence， while the disorder of ascending and descending is the pivot of the disease development， and the generation of yin fire is the convergence of malignant tumor progression. Based on this， the three major therapeutic methods of clearing the source， harmonizing the pivot， and resolving the convergence are established. To fortify spleen and boost qi， consolidate the root and clear the source， modified Buzhong Yiqi Decoction（补中益气汤）can be used. To raise the clear and direct the turbid downward， regulate qi and harmonize the pivot， modified Shengyang Yiwei Decoction （升阳益胃汤） is suggested. To restore balance and promote circulation， disperse accumulation and resolve convergence， modified Shengyang Sanhuo Decoction （升阳散火汤） is selected. In clinical practice， these formulas can be used in combination according to the complexity of the pathogenesis， and further adapted with prescriptions for promoting dispersion and penetrating pathogenic factors， resolving phlegm and promoting circulation， activating blood and eliminating concretions， which can provide a reference for the prevention and treatment of tumor diseases.

Based on LI Gao's Academic Thought， focusing on the process of qi transformation and taking the regulation and restoration of metabolism and immunity as the entry point， a "source-pivot-convergence" diagnostic and therapeutic model for malignant tumors is constructed. In this model， spleen and stomach internal injury is the source of malignant tumor occurrence， while the disorder of ascending and descending is the pivot of the disease development， and the generation of yin fire is the convergence of malignant tumor progression. Based on this， the three major therapeutic methods of clearing the source， harmonizing the pivot， and resolving the convergence are established. To fortify spleen and boost qi， consolidate the root and clear the source， modified Buzhong Yiqi Decoction（补中益气汤）can be used. To raise the clear and direct the turbid downward， regulate qi and harmonize the pivot， modified Shengyang Yiwei Decoction （升阳益胃汤） is suggested. To restore balance and promote circulation， disperse accumulation and resolve convergence， modified Shengyang Sanhuo Decoction （升阳散火汤） is selected. In clinical practice， these formulas can be used in combination according to the complexity of the pathogenesis， and further adapted with prescriptions for promoting dispersion and penetrating pathogenic factors， resolving phlegm and promoting circulation， activating blood and eliminating concretions， which can provide a reference for the prevention and treatment of tumor diseases.

Objective To investigate the level and significance of serum suprabasin(SBSN)in patients with colorectal cancer(CRC).Methods A total of 200 patients with CRC in Nanjing Medical University Af-filiated Cancer Hospital from October 2023 to October 2024 were selected as the CRC group,200 patients with colorectal polyps were selected as the benign bowel disease(BCD)group,and 177 healthy people were selected as the control group.In addition,the serum SBSN levels of 84 CRC patients 7-10 d after surgery were collect-ed.The levels of SBSN in each group were compared,and the relationship between serum SBSN level and clin-icopathological characteristics of CRC patients was analyzed.Multivariate Logistic regression was used to ana-lyze the influencing factors of CRC.The receiver operating characteristic(ROC)curve was used to analyze the diagnostic efficacy of serum SBSN alone and in combination with carcinoembryonic antigen(CEA)and carbo-hydrate antigen 19-9(CA19-9)for CRC.Results The serum SBSN level in CRC group was significantly high-er than that in BCD group and control group(P＜0.001).Serum SBSN level in CRC patients was associated with TNM stage and lymph node metastasis(both P=0.001),but not with other clinicopathological features(P＞0.05).Serum SBSN,CEA,CA19-9 were independent risk factors for CRC(P＜0.001).ROC curve anal-ysis showed that the area under the curve(AUC)of SBSN alone in the diagnosis of CRC was 0.734,which was higher than that of CEA(0.611)and CA19-9(0.669)alone,and the AUC of the three combined diagno-sis of CRC was 0.816.The sensitivity and specificity were 70.0％and 81.4％,respectively.The serum SBSN level of CRC patients decreased after operation,and the difference was statistically significant compared with that before operation(P＜0.05).Conclusion SBSN is associated with the occurrence,metastasis and progno-sis of colorectal cancer,and has a certain clinical value in the diagnosis and prediction of colorectal cancer.Ser-um SBSN is a potential biomarker for the auxiliary diagnosis of colorectal cancer.

Objective To construct large medical model named by "Huaxi HongYi"and explore its application effectiveness in assisting medical record generation. Methods By the way of a full-chain medical large model construction paradigm of "data annotation - model training - scenario incubation", through strategies such as multimodal data fusion, domain adaptation training, and localization of hardware adaptation, "Huaxi HongYi" with 72 billion parameters was constructed. Combined with technologies such as speech recognition, knowledge graphs, and reinforcement learning, an application system for assisting in the generation of medical records was developed. Results Taking the assisted generation of discharge records as an example, in the pilot department, after using the application system, the average completion times of writing a medical records shortened (21 min vs. 5 min) with efficiency increased by 3.2 time, the accuracy rate of the model output reached 92.4%. Conclusion It is feasible for medical institutions to build independently controllable medical large models and incubate various applications based on these models, providing a reference pathway for artificial intelligence development in similar institutions.

OBJECTIVE: To assess the relationship between blood pressure reactivity index (BPRI) and in-hospital mortality risk in patients with sepsis-associated acute kidney injury (SA-AKI). METHODS: A retrospective cohort study was conducted to collect data from patients admitted to the intensive care unit (ICU) and clinically diagnosed with SA-AKI between 2008 and 2019 in the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database in the United States. The collected data included demographic characteristics, comorbidities, vital signs, laboratory parameters, sequential organ failure assessment (SOFA) and simplified acute physiology scoreII(SAPSII) within 48 hours of SA-AKI diagnosis, stages of AKI, treatment regimens, mean BPRI during the first and second 24 hours (BPRI_0_24, BPRI_24_48), and outcome measures including primary outcome (in-hospital mortality) and secondary outcomes (ICU length of stay and total hospital length of stay). Variables with statistical significance in univariate analysis were included in LASSO regression analysis for variable selection, and the selected variables were subsequently incorporated into multivariate Logistic regression analysis to identify independent predictors associated with in-hospital mortality in SA-AKI patients. Restricted cubic spline (RCS) analysis was employed to examine whether there was a linear relationship between BPRI within 48 hours and in-hospital mortality in SA-AKI patients. Basic prediction models were constructed based on the independent predictors identified through multivariate Logistic regression analysis, and receiver operator characteristic curve (ROC curve) was plotted to evaluate the predictive performance of each basic prediction model before and after incorporating BPRI. RESULTS: A total of 3 517 SA-AKI patients admitted to the ICU were included, of whom 826 died during hospitalization and 2 691 survived. The BPRI values within 48 hours of SA-AKI diagnosis were significantly lower in the death group compared with the survival group [BPRI_0_24: 4.53 (1.81, 8.11) vs. 17.39 (5.16, 52.43); BPRI_24_48: 4.76 (2.42, 12.44) vs. 32.23 (8.85, 85.52), all P < 0.05]. LASSO regression analysis identified 20 variables with non-zero coefficients that were included in the multivariate Logistic regression analysis. The results showed that respiratory rate, temperature, pulse oxygen saturation (SpO₂), white blood cell count (WBC), hematocrit (HCT), activated partial thromboplastin time (APTT), lactate, oxygenation index, SOFA score, fluid balance (FB), BPRI_0_24, and BPRI_24_48 were all independent predictors for in-hospital mortality in SA-AKI patients (all P < 0.05). RCS analysis revealed that both BPRI showed "L"-shaped non-linear relationships with the risk of in-hospital mortality in SA-AKI patients. When BPRI_0_24 ≤ 14.47 or BPRI_24_48 ≤ 24.21, the risk of in-hospital mortality in SA-AKI increased as BPRI values decreased. Three basic prediction models were constructed based on the identified independent predictors: Model 1 (physiological indicator model) included respiratory rate, temperature, SpO₂, and oxygenation index; Model 2 (laboratory indicator model) included WBC, HCT, APTT, and lactate; Model 3 (scoring indicator model) included SOFA score and FB. ROC curve analysis showed that the predictive performance of the basic models ranked from high to low as follows: Model 3, Model 2, and Model 1, with area under the curve (AUC) values of 0.755, 0.661, and 0.655, respectively. The incorporation of BPRI indicators resulted in significant improvement in the discriminative ability of each model (all P < 0.05), with AUC values increasing to 0.832 for Model 3+BPRI, 0.805 for Model 2+BPRI, and 0.808 for Model 1+BPRI. CONCLUSIONS BPRI is an independent predictor factor for in-hospital mortality in SA-AKI patients. Incorporating BPRI into the prediction model for in-hospital mortality risk in SA-AKI can significantly improve its predictive capability.
Humans ; Acute Kidney Injury/mortality* ; Sepsis/complications* ; Retrospective Studies ; Hospital Mortality ; Prognosis ; Blood Pressure ; Intensive Care Units ; Male ; Female ; Length of Stay ; Middle Aged ; Aged ; Adult ; Logistic Models

Chronic stress triggers the imbalance of the homeostasis of the tumor immune microenvironment(TIME),which is a key factor driving the development of lung cancer.Based on the mapping relationship between the concept of"spirit"in traditional Chinese medicine and chronic stress,and between"qi"and"immunity",it is believed that the cross-linking mechanism of"chronic stress-TIME-lung cancer"aligns with the understanding of traditional Chinese medicine of disease as involving the interplay between the"body,qi and spirit".The disorganization of"spirit"and"qi"is not only the root of the change of the"form",but also the key to prevent and control it.The treatment principle of synergizing to improve the chronic stress of"regulating the spirit"and remodeling the TIME of"invigorating the qi"is further proposed,which emphasizes on grasping the core pathogenesis of lung cancer at each stage of its evolution in order to administer medicines,drawing on the clinical experience and pharmacological research results in order to accurately hit the target,and combining special therapies like acupuncture,Chinese kungfu,sound therapy to treat the change of"shape"by modulating neuro-endocrine-immune network homeostasis,so as to provide new ideas and accessible solutions for the comprehensive prevention and treatment system of lung cancer.

Objective:To assess the diagnostic performance of a panel of autoantibodies against multiple tumor-associated antigens (BRCA2, P53, ANXA11, PARP1, TRIM21, ATAD2, NY-ESO-1 and CAGE) in the detection of breast cancer.Methods:This was a retrospective case-control study. A total of 545 patients diagnosed with breast cancer (BC) by pathological examination, and eligible for enrolment at Jiangsu Cancer Hospital from January 2022 to December 2023 were selected as the patient group. In the same period, 200 patients with benign breast disease (BD) and 200 healthy individuals (HC) were included. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of tumor-associated autoantibodies in each group. The tumor markers including carcinoembryonic antigen (CEA), glycoconjugate antigen 125 (CA125) and glycoconjugate antigen 153 (CA153) were detected using electrochemiluminescence. Univariate and multivariate logistic regression analyses were used to screen the factors associated with breast cancer. The receiver operating characteristic (ROC) curve was applied to evaluate diagnostic value.Results:The levels of seven autoantibodies against BRCA2, P53, ANXA11, PARP1, ATAD2, NY-ESO-1 and CAGE were significantly higher in the BC group compared to HC group (all P<0.05). Additionally, the levels of six autoantibodies against BRCA2, P53, PARP1, ATAD2, NY-ESO-1 and CAGE were significantly higher in the BC group than those in BD group (all P<0.05). The levels of PARP1 and ATAD2 in the BD group were higher than those in HC group ( P<0.05). Logistic multivariate analysis revealed that BRCA2 ( OR=1.099, 95% CI 0.824-1.107), P53 ( OR=1.534, 95% CI 0.813-2.898), NY-ESO-1( OR=1.159, 95% CI 0.789-1.712) and CA153 ( OR=1.029, 95% CI 0.778-1.495) were potential indicators for breast cancer (all P<0.05). The ROC curves indicated that the AUCs for breast cancer using BRCA2, P53, NY-ESO-1, and CA153 were 0.602 (95% CI 0.549-0.635), 0.688 (95% CI 0.642-0.734), 0.729 (95% CI 0.677-0.781), 0.714 (95% CI 0.663-0.764), respectively. The sensitivities were 0.405, 0.588, 0.683 and 0.653, while the specificities were 0.770, 0.825, 0.851 and 0.790, respectively. The AUC of the combined detection including BRCA2, P53, NY-ESO-1, and CA153 for breast cancer was 0.857 (95% CI 0.832-0.883), with a sensitivity of 0.719 and a specificity of 0.835. Conclusions:The levels of tumor-associated autoantibodies to BRCA2, P53 and NY-ESO-1 were significantly elevated in breast cancer patients, and the combination of the three autoantibodies and CA153 has high diagnostic value for breast cancer.

Objective:To assess the diagnostic performance of a panel of autoantibodies against multiple tumor-associated antigens (BRCA2, P53, ANXA11, PARP1, TRIM21, ATAD2, NY-ESO-1 and CAGE) in the detection of breast cancer.Methods:This was a retrospective case-control study. A total of 545 patients diagnosed with breast cancer (BC) by pathological examination, and eligible for enrolment at Jiangsu Cancer Hospital from January 2022 to December 2023 were selected as the patient group. In the same period, 200 patients with benign breast disease (BD) and 200 healthy individuals (HC) were included. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of tumor-associated autoantibodies in each group. The tumor markers including carcinoembryonic antigen (CEA), glycoconjugate antigen 125 (CA125) and glycoconjugate antigen 153 (CA153) were detected using electrochemiluminescence. Univariate and multivariate logistic regression analyses were used to screen the factors associated with breast cancer. The receiver operating characteristic (ROC) curve was applied to evaluate diagnostic value.Results:The levels of seven autoantibodies against BRCA2, P53, ANXA11, PARP1, ATAD2, NY-ESO-1 and CAGE were significantly higher in the BC group compared to HC group (all P<0.05). Additionally, the levels of six autoantibodies against BRCA2, P53, PARP1, ATAD2, NY-ESO-1 and CAGE were significantly higher in the BC group than those in BD group (all P<0.05). The levels of PARP1 and ATAD2 in the BD group were higher than those in HC group ( P<0.05). Logistic multivariate analysis revealed that BRCA2 ( OR=1.099, 95% CI 0.824-1.107), P53 ( OR=1.534, 95% CI 0.813-2.898), NY-ESO-1( OR=1.159, 95% CI 0.789-1.712) and CA153 ( OR=1.029, 95% CI 0.778-1.495) were potential indicators for breast cancer (all P<0.05). The ROC curves indicated that the AUCs for breast cancer using BRCA2, P53, NY-ESO-1, and CA153 were 0.602 (95% CI 0.549-0.635), 0.688 (95% CI 0.642-0.734), 0.729 (95% CI 0.677-0.781), 0.714 (95% CI 0.663-0.764), respectively. The sensitivities were 0.405, 0.588, 0.683 and 0.653, while the specificities were 0.770, 0.825, 0.851 and 0.790, respectively. The AUC of the combined detection including BRCA2, P53, NY-ESO-1, and CA153 for breast cancer was 0.857 (95% CI 0.832-0.883), with a sensitivity of 0.719 and a specificity of 0.835. Conclusions:The levels of tumor-associated autoantibodies to BRCA2, P53 and NY-ESO-1 were significantly elevated in breast cancer patients, and the combination of the three autoantibodies and CA153 has high diagnostic value for breast cancer.

Objective To explore the role of ring finger protein 41(RNF41)in the initiation and progression of cholangiocarcinoma.Methods The expression levels of RNF41 mRNA and protein in tumor tissues and adjacent normal tissues from 84 CHOL patients who underwent total surgical resection at the Second Affiliated Hospital of Kunming Medical University and Kunming Ganmei Hospital between January 2010 and December 2016 were analyzed using bioinformatics,Western blot,and immunohistochemistry.The TIMER 2.0 database was used to analyze the impact of RNF41 on the prognosis and survival of CHOL patients and the relationship between RNF41 and tumor clinical characteristics.RNF41 siRNA was transfected into HCC9810,RBE,and HUCCT1 cells.CCK-8,Edu,colony formation,and Western blot assays were conducted to evaluate the changes in proliferation of cholangiocarcinoma cells between the RNF41 knockdown group and the control group.Transwell assays and detection of EMT and migration markers were performed to assess changes in the invasion ability of cholangiocarcinoma cells between the RNF41 knockdown and control groups.Western blot was used to examine the effect of RNF41 knockdown on epithelial-mesenchymal transition in cholangiocarcinoma cells.Twelve BALB/c mice were randomly divided into two groups:a control group and an RNF41 knockdown group,with six mice in each group.Tumor formation assays,Western blot assays,and immunohistochemistry staining were carried out to investigate the effect of RNF41 knockdown on tumor growth in nude mice.Results Real-time quantitative fluorescence PCR analysis revealed that the expression level of RNF41 mRNA in cholangiocarcinoma tissues was significantly higher than that in the corresponding adjacent non-tumor tissues(P<0.01),and this trend was corroborated at the protein level by immunohistochemical staining.Using the TIMER 2.0 database,we further analyzed the correlation between RNF41 expression and clinicopathological features,including histological grade,tumor stage,lymph node metastasis,and patient survival.The results indicated that elevated RNF41 expression was significantly associated with advanced histological grade and lymph node metastasis in cholangiocarcinoma(P<0.01).Survival analysis demonstrated that high RNF41 expression was closely linked to poor prognosis in patients with cholangiocarcinoma(CHOL).Functional assays,including CCK-8,EdU incorporation,and colony formation,showed that RNF41 knockdown significantly inhibited the proliferation of cholangiocarcinoma cells compared with the control group.Western blot analysis revealed that,following RNF41 silencing,the expression of the epithelial-mesenchymal transition(EMT)marker E-cadherin was markedly upregulated,whereas the levels of mesenchymal markers N-cadherin and MMP9 were significantly reduced(P<0.05).These findings were consistent with the results obtained from in vitro experiments(P<0.01).Moreover,in vivo studies showed that RNF41 knockdown suppressed subcutaneous tumor formation in nude mice(P<0.05).Conclusion RNF41 plays a critical role in promoting the occurrence and progression of cholangiocarcinoma and is closely associated with adverse clinicopathological features and poor prognosis in patients.The knockdown of RNF41 effectively suppresses the proliferation,invasion,epithelial-mesenchymal transition(EMT),and tumorigenicity of cholangiocarcinoma cells.